OncoMatch/Clinical Trials/NCT05411718
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Is NCT05411718 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Naproxen and Aspirin for t cells.
Treatment: Naproxen · Aspirin — To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MLH1 pathogenic mutation
carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2/EPCAM, MSH6, or PMS2)
Required: MSH2 pathogenic mutation
carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2/EPCAM, MSH6, or PMS2)
Required: EPCAM pathogenic mutation
carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2/EPCAM, MSH6, or PMS2)
Required: MSH6 pathogenic mutation
carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2/EPCAM, MSH6, or PMS2)
Required: PMS2 pathogenic mutation
carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the DNA mismatch repair (MMR) genes (i.e., MLH1, MSH2/EPCAM, MSH6, or PMS2)
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin >10 g/dL or Hematocrit > 30 %; Leukocyte count ≥3,000/microliter; Platelet count ≥100,000/microliter; Absolute neutrophil count ≥1,500/microliter
Kidney function
Creatinine ≤1.5 x institutional ULN (OR GFR >30ml/min/1.73m2)
Liver function
Total bilirubin ≤2 x institutional ULN; AST (SGOT) ≤2.5 × institutional ULN; ALT (SGPT) ≤2.5 × institutional ULN
Participants must have normal organ and marrow function as defined below: Hemoglobin >10 g/dL or Hematocrit > 30 % Leukocyte count ≥3,000/microliter Platelet count ≥100,000/microliter Absolute neutrophil count ≥1,500/microliter Creatinine ≤1.5 x institutional ULN (OR GFR >30ml/min/1.73m2) Total bilirubin ≤2 x institutional ULN AST (SGOT) ≤2.5 × institutional ULN ALT (SGPT) ≤2.5 × institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify